The goal of the Start-Up Stadium is to increase engagement with investors, state and regional affiliates, early-stage companies at the beginning of their life-cycle and the burgeoning ecosystem in which they play. This provides resources that boost the biotechnology industry as well as a clear, successful example to stakeholders that early-stage innovation is well represented at the BIO International Convention.
Through the widespread outreach of this event, we plan to reach entrepreneurial ecosystems in all 50 states and abroad. We plan to reach some of the most overlooked regions for start-ups, which traditionally have limited access to investor engagement, feedback, and representation at the BIO International Convention.
During the BIO International Convention, investor judges attend live presentations and engage in a Q&A providing feedback to finalists. Finalists will participate in one of five sessions in 2-3 days among 40+ companies. You present a 6 minute pitch, followed by written and oral feedback from investor judges. We encourage participants to request and schedule BIO One-on-One Partnering meetings before you arrive to Boston (make sure to keep your schedule up to date!)
After the event, BIO collects feedback from start-ups and judges and analyzes the increased engagement between investors and early-stage communities. In late July, BIO follows up with finalists for product and investment status.
Participating in the BIO Start-Up Stadium provides a great opportunity to be featured in an innovative space that drives start-ups and investors to engage and explore opportunities for cutting-edge achievements. Here's how to participate:
Started in 2015, Start-Up Stadium presented an opportunity for BIO to engage start-ups in the North East region of the United States (NY, NJ, PA) and support companies whose sole purpose is to develop cutting-edge technologies and therapeutic solutions, become commercially viable and have a real and sustained industry impact. We used this platform to assist start-ups in gaining visibility in front of the investment community, attaining live feedback from investor judges, and accessing BIO One-on-One Partnering and educational sessions.
In 2016, BIO engaged the biotech and pharma start-ups on the West Coast in order to continue building the support structure needed to help early-stage companies become commercially viable and create live-saving treatments. The presenters at this innovative event became part of the overall resource partner network, reaching a constituency that we were not effectively reaching before.
For 2017, BIO expanded access to this unique approach to all domestic and international biotech and pharma start-ups.